Online Program Home
My Program

Sessions Were Renumbered as of May 19.

CC-W = McCormick Place Convention Center, West Building,   CC-N = McCormick Place Convention Center, North Building
H = Hilton Chicago,   UC= Conference Chicago at University Center
* = applied session       ! = JSM meeting theme

Activity Details

CE_13C Sun, 7/31/2016, 1:00 PM - 5:00 PM CC-W470b
Making Quantitative Decisions During the Clinical Development of a New Drug (ADDED FEE) — Professional Development Continuing Education Course
ASA , Biopharmaceutical Section
There are many decision points during the clinical development of a new drug. These decisions have traditionally been based on the hypothesis-testing framework where type-I error and power requirements drive the sample size calculation. In this course, we will take a different approach by treating clinical trials as a series of diagnostic tests in which the goal is to estimate the likelihood that a drug has the desired profile. Treating a trial as a diagnostic test translates the concept of power and type-I error rate of the former to the sensitivity and 1-specificity of the latter. Positive predictive value now refers to the probability that a new drug has the desired properties. This analogy facilitates formal incorporation of evidence from a previous trial into the design of a future trial and the subsequent decision criteria, allowing the formulation of go/no-go criteria that can address the unique needs of different stages of the clinical testing. Using the above analogy, we will discuss different metrics relevant to decision making at the proof-of-concept, dose-response, and confirmatory stages. We show how appropriate metrics may enable better decisions and illustrate several potential mistakes trialists should guard against. Examples will be offered throughout the course.
Instructor(s): Christy Chuang-Stein, Independent Consultant
Copyright © American Statistical Association